OptiNose (OPTN) Projected to Post Quarterly Earnings on Thursday

OptiNose (NASDAQ:OPTN) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $21.02 million for the quarter.

OptiNose Stock Performance

OPTN opened at $5.65 on Thursday. The company’s 50 day simple moving average is $6.02 and its 200 day simple moving average is $9.17. OptiNose has a 1 year low of $4.82 and a 1 year high of $31.50. The stock has a market capitalization of $56.84 million, a PE ratio of -1.35 and a beta of -0.17.

Analyst Ratings Changes

OPTN has been the topic of several research reports. Lake Street Capital cut their price target on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. HC Wainwright lifted their price objective on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, Piper Sandler dropped their price objective on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.